MDSC, CSC and the clusters in blood from NSCLC patients will be assessed to evaluate the impact of G-CSF on their phenotype and functions. Samples from 2 groups of NSCLC patients receiving chemotherapy and immunotherapy will be used: 15 receiving concomitant G-CSF, and 15 not receiving concomitant G-CSF
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients (male or female) aged ≥ 18 years
Histological or cytological proven lung adenocarcinoma, metastatic or locally advanced not accessible to local therapy
Receiving chemotherapy and immunotherapy as first-line treatment
Signed written informed consent (no later than the day of inclusion, and before the blood sample collection)
Patient affiliated or beneficiary to a health security system;
You may not be if
Patient with a small cell lung carcinoma
Non-metastatic disease
Actionable mutation or genomic alteration in EGFR, ALK or ROS1
Corticosteroids \> 10 mg/j
Autoimmune disease
Active and uncontrolled HIV infection
Concomitant cancer
Pregnancy or lactating women
Psychiatric or medical conditions that prohibit the understanding and rendering of informed consent
Patient under a legal protection measure
Patient with a deprived liberty condition
Patient incapable of giving signed informed consent
Patient within the exclusion period for another clinical trial, or participating to another interventional trial within 30 days before the beginning of this project